RT Journal Article
SR Electronic
T1 Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5291
OP 5294
DO 10.21873/anticanres.14534
VO 40
IS 9
A1 UMAIR M. NASIR
A1 ALEXANDER M. MOZEIKA
A1 MUTLAY SAYAN
A1 IMRAAN JAN
A1 NOEL KOWAL
A1 BRUCE HAFFTY
A1 SUSHIL AHLAWAT
A1 NEIL KOTHARI
YR 2020
UL http://ar.iiarjournals.org/content/40/9/5291.abstract
AB Background/Aim: Palbociclib is an FDA-approved cyclin-dependent kinase inhibitor for the treatment of advanced breast cancer. Limited information is available regarding the toxicity of palbociclib and concurrent radiation therapy. Case Report: Herein, we report a case of esophageal toxicity in a patient treated with palbociclib and radiation therapy. A 63-year-old woman was treated with palbociclib followed by palliative radiation therapy. The patient presented three days after completing radiation therapy with severe odynophagia, and dysphagia and was found to have grade 2-3 esophageal ulcers. Palbociclib and radiation therapy was held on admission, and a resolution of her symptoms and improvement in her oral intake was noted at which time she was restarted on palbociclib with no further radiation treatment. Conclusion: Caution is advised when patients are undergoing concurrent palbociclib and even low-dose palliative radiation treatment. In these patients, providers should maintain a high index of suspicion for toxicities such as dermatitis or mucositis.